Information Provided By:
Fly News Breaks for September 16, 2019
AIMT
Sep 16, 2019 | 07:34 EDT
Roth Capital analyst Zegbeh Jallah says that Aimmune's overwhelmingly positive vote from the APAC does not only increase Palforzia's odds of approval by the FDA in January for peanutallergic children ages 4-7, but also derisks the entire pipeline. With Palforzia's approval now almost a certainty and with the significant progress Aimmune has made on the commercial front, the analyst remains bullish on the commercial opportunity. He reiterates a Buy rating and $45 price target on the shares.
News For AIMT From the Last 2 Days
There are no results for your query AIMT